Germline RAD51B Variants Confer Susceptibility to Breast and Ovarian Cancers Deficient in Homologous Recombination

Investigators demonstrated that tumors harboring biallelic RAD51B alteration were deficient in homologous recombination DNA repair deficiency, as evidenced by analysis of sequencing data and in vitro functional assays.
[npj Breast Cancer]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Niraparib Exhibits a Synergistic Anti-Tumor Effect with PD-L1 Blockade by Inducing an Immune Response in Ovarian Cancer

Programmed death ligand 1 (PD-L1) expression in human ovarian cancer cells after PARP inhibitors treatment was examined by western blotting and flow cytometry.
[Journal of Translational Medicine]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

T-Cure Bioscience Announces US FDA Clearance of Investigator-Initiated Clinical Trial for KK-LC-1 TCR-T against Multiple Solid Tumors

T–Cure Bioscience, Inc. announced that the US FDA has approved the Investigational New Drug application to initiate a Phase I clinical study evaluating a T cell receptor (TCR)–based product candidate for the treatment of tumors expressing Kita–Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, lung, breast cancers and other KK–LC–1 positive epithelial cancers.
[T–Cure Bioscience, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

State Stem Cell Agency Funds Three New UC San Diego Projects

The governing Board of the California Institute for Regenerative Medicine has approved a trio of awards, totaling approximately $4 million, to University of California San Diego School of Medicine researchers to advance studies of new stem cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis.
[UC San Diego Health]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Synergistic Targeting of BRCA1 Mutated Breast Cancers with PARP and CDK2 Inhibition

In cell lines, BRCA1 loss was associated with stabilized cyclin E1 during the cell cycle, and BRCA1 siRNA led to increased cyclin E1 in association with reduced phospho-cyclin E1 T62.
[npj Breast Cancer]
[zotpress userid=’7992332′ items=’LVJ2LSCB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Extracellular Matrix Mediates Moruloid-Blastuloid Morphodynamics in Malignant Ovarian Spheroids

Ultrastructural examination reveals a basement membrane-like extracellular matrix coat on the surface of blastuloid, but not moruloid, spheroids.
[Life Science Alliance]
[zotpress userid=’6445218′ items=’B7N6V7WQ’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Lapatinib and Poziotinib Overcome ABCB1-Mediated Paclitaxel Resistance in Ovarian Cancer

Investigators established in vitro paclitaxel-resistant ovarian cancer cell line and organoid models. Gene expression differences in resistant and sensitive lines were analyzed by RNA sequencing.
[PLoS One]
[zotpress userid=” items=’MRIXQI2B’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Development and In Vitro Characterisation of an Induced Pluripotent Stem Cell Model of Ovarian Cancer

An ovarian cancer cell line, PEO4, was initially reprogrammed into induced pluripotent stem cells using the classical four factors OCT4, SOX2, KLF4 and MYC using lentivirus transduction.
[International Journal of Biochemistry & Cell Biology]
[zotpress userid=” items=’P3TCWD6S’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Development and In Vitro Characterization of an Induced Pluripotent Stem Cell Model of Ovarian Cancer

An ovarian cancer cell line, PEO4, was reprogrammed into iPSCs using the classical four factors OCT4, SOX2, KLF4 and MYC (OSKM) using lentivirus transduction.
[International Journal of Biochemistry & Cell Biology]
[zotpress userid=’7992332′ items=’XGWK4YGI’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Exploiting Epigenetic Dependencies in Ovarian Cancer Therapy

The authors review the major developments in ovarian cancer, including genetics, model systems and technologies available for their study and the implications of applying epigenetic therapies to ovarian cancer.
[International Journal of Cancer]
[zotpress userid=” items=’QCIM7YDC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

INmune Bio, Inc. Announces First Patient Treated with NK Cell Priming “Pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.
[INmune Bio, Inc.]
[zotpress userid=’7992332′ items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share
Share